Previous 10 | Next 10 |
2024-02-12 03:08:36 ET Summary Twist Bioscience specializes in synthetic biology and DNA applications, focusing on synthetic DNA, DNA products, and Next-Generation Sequencing tools. The company's revenue-generating segments, particularly DNA synthesis, show high growth and cost re...
2024-02-07 09:22:26 ET Summary Twist Bioscience reported strong results in the first quarter of FY2024, despite a tepid demand environment. Growth was somewhat exaggerated by lumpy NGS revenue, but overall the business is progressing well, particularly from a profitability perspec...
Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow expected to be available soon Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosc...
High accuracy and detection to identify tumor variants from degraded and low input samples as well as samples with limited DNA abundance Library preparation kit adds to Twist’s portfolio of tools to enable liquid biopsy applications Twist Bioscience Corporation (NASDAQ: TWS...
Early access of novel technology that enables preparation of thousands of samples at low cost through self-normalization, enhanced multiplexing, and streamlined workflow Innovative solution positioned to drive NGS adoption in AgBio Twist Flex Prep UHT Kit and additional NGS tools to be hi...
2024-02-02 13:11:04 ET Twist Bioscience Corporation (TWST) Q1 2024 Earnings Conference Call February 2, 2024 08:00 AM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs Emily Leproust - Chief Executive Officer & Co-Founder Adam ...
2024-02-02 07:34:45 ET More on Twist Bioscience Twist Bioscience: Continued Progress Despite Headwinds Twist Bioscience expands express genes service Seeking Alpha’s Quant Rating on Twist Bioscience Read the full article on Seeking Alpha For fu...
– Record revenue of $71.5M in 1QFY24, an increase of 32% over $54.2M in 1QFY23 – – Orders increased to $77.5M in 1QFY24, an increase of 19% over 1QFY23 – — Increased FY 2024 revenue guidance to $288M to $293M; Increased FY 2024 gross margin guidance to 4...
Atlas Lithium Corporation (ATLX) is expected to report $-0.47 for Q4 2023 Capital Product Partners L.P. (CPLP) is expected to report $0.7 for Q4 2023 WisdomTree Inc. (WT) is expected to report $0.11 for Q4 2023 Mitsubishi Corporation (MSBHF) is expected to report for Q3 2024 C3is ...
2024-02-01 11:40:33 ET More on Twist Bioscience Twist Bioscience: Continued Progress Despite Headwinds Twist Bioscience Corporation (TWST) Q4 2023 Earnings Call Transcript Twist Bioscience expands express genes service Goldman ups Twist Bioscience to buy, cit...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
2024-06-28 07:15:04 ET Barclays analyst issues OVERWEIGHT recommendation for TWST on June 28, 2024 05:29AM ET. The previous analyst recommendation was Overweight. TWST was trading at $47.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
TB206-001 shown to be a high-affinity, cross-reactive humanized antibody antagonist of A 2A R with in vivo tumor suppressing activity TB206-001 available for out-licensing Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering...
Twist Bioscience Corporation (NASDAQ: TWST) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 11.58% on the day to $52.42. Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-bas...